Senti Bio to Participate in Upcoming Investor Conferences
03 sept. 2024 08h15 HE
|
Senti Biosciences, Inc.
Senti Bio will participate in two upcoming investor conferences in September.
Cambrium Secures €8 Million in Seed Funding to Commercialize New Class of Performance Molecules
31 oct. 2023 07h00 HE
|
Cambrium GmbH
Synthetic biology startup Cambrium announces €8 Million in Seed financing, led by Essential Capital, along with SNR, Valor Equity Partners, and HOF Capital
Synlogic Announces Data Presentations at the 2023 Synthetic Biology: Engineering, Evolution & Design (SEED) Conference
24 mai 2023 06h35 HE
|
Synlogic, Inc.
CAMBRIDGE, Mass., May 24, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), the leading company advancing therapeutics based on synthetic biology, today announced its planned presentations at...
Synlogic to Present at the Jefferies Global Healthcare Conference
23 mai 2023 06h50 HE
|
Synlogic, Inc.
CAMBRIDGE, Mass., May 23, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), the leading company advancing therapeutics based on synthetic biology, today announced that Aoife Brennan, M.B....
Synlogic Reports First Quarter 2023 Financial Results and Provides Business Update
11 mai 2023 06h50 HE
|
Synlogic, Inc.
- Phenylketonuria (PKU) program on track for Phase 3 trial initiation in first half of 2023 – - Recent milestones include receipt of Rare Pediatric and Orphan Drug Designations from the FDA, and...
Synlogic Receives Orphan Drug Designation from FDA for SYNB1934 for Treatment of Phenylketonuria
09 mai 2023 06h50 HE
|
Synlogic, Inc.
CAMBRIDGE, Mass., May 09, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), the leading company advancing therapeutics based on synthetic biology, today announced that the U.S. Food and Drug...
Synlogic Reports Fourth Quarter and Full Year 2022 Financial Results and Corporate Updates
29 mars 2023 06h40 HE
|
Synlogic, Inc.
– Phenylketonuria (PKU) program on track for Phase 3 trial initiation in first half of 2023 – – Rare Pediatric Disease Designation granted for SYNB1934 for PKU and SYNB1353 for homocystinuria (HCU)...
Synlogic Receives Positive Opinion on Orphan Designation from the European Medicines Agency for SYNB1934 for the Treatment of Phenylketonuria
28 mars 2023 06h52 HE
|
Synlogic, Inc.
CAMBRIDGE, Mass., March 28, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), the leading company advancing therapeutics based on synthetic biology, today announced that the European Medicines...
Synlogic Announces Data Presentations at the Society for Inherited Metabolic Disorders (SIMD) 44th Annual Meeting
20 mars 2023 06h55 HE
|
Synlogic, Inc.
CAMBRIDGE, Mass., March 20, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), the leading company advancing therapeutics based on synthetic biology, announced that positive data from the...
Synlogic to Present at the Oppenheimer 33rd Annual Healthcare Conference
08 mars 2023 07h00 HE
|
Synlogic, Inc.
CAMBRIDGE, Mass., March 08, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), the leading company advancing therapeutics based on synthetic biology, today announced that Aoife Brennan, M.B....